Agenus Inc. diskutieren

Sell Agenus Inc.

Buy Agenus Inc.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $8.30 price target on the stock.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $8.00 price target on the stock.

Agenus Inc. (NASDAQ: AGEN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

Agenus Inc. (NASDAQ: AGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.

Agenus, a biotech company, has been making waves with its innovative immunotherapy pipeline. The recent appointment of Dr. Jennifer Buell to its board of directors is a positive sign, bringing in valuable expertise to guide the company's strategic direction. Moreover, the promising clinical data on Agenus' novel immunotherapy against a deadly form of colorectal cancer is encouraging. This type of cancer is on the rise among younger Americans, and Agenus' potential breakthrough could be a game-changer in addressing this pressing healthcare issue. While the current stock price of $0.4138 may seem low, I believe Agenus has the potential to deliver solid returns in the long run as its pipeline continues to progress. The company's focus on innovative cancer treatments aligns with the growing demand for effective therapies, and I am optimistic about Agenus' ability to capitalize on this opportunity. With a target price of $0.6, I believe Agenus is a solid buy for investors willing to take on the inherent risks of the biotech industry.

Agenus Inc. (NASDAQ: AGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.